Literature DB >> 12500070

Ziprasidone-associated galactorrhea in a female teenager.

Mirlande P Jordan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12500070     DOI： 10.1097/00004583-200301000-00004

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN： 0890-8567            Impact factor:   8.829


× No keyword cloud information.
  7 in total

1.  Ziprasidone-induced galactorrhea in an adolescent female: a case report.

Authors:  Shakeel Raza; Fasiha Haq
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Hyperprolactinemia with antipsychotic drugs in children and adolescents.

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2010-08-24

4.  Focus on ziprasidone: a review of its use in child and adolescent psychiatry.

Authors:  Dean Elbe; Carlo G Carandang
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-11

Review 5.  Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone.

Authors:  Afshan A Khan; Jeffrey R Strawn; Paul E Croarkin
Journal:  Adolesc Health Med Ther       Date:  2010-10-11

Review 6.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

7.  Evidence review and clinical guidance for the use of ziprasidone in Canada.

Authors:  David M Gardner; Andrea L Murphy; Stan Kutcher; Serge Beaulieu; Carlo Carandang; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Claire O'Donovan; Ayal Schaffer; Jorge Soni; Valerie H Taylor; Richard Williams
Journal:  Ann Gen Psychiatry       Date:  2013-01-24       Impact factor: 3.455
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.